{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.45","value":"-1.5"},{"groupId":"OG001","spread":"2.35","value":"-2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"326"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"title":"Week 4 (n=326,350)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.66","value":"-1.9"},{"groupId":"OG001","spread":"2.62","value":"-2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"267"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"title":"Week 10 (n=267,305)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.79","value":"-2.1"},{"groupId":"OG001","spread":"2.46","value":"-2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"254"}],"units":"Participants"}],"title":"Week 16 (n=244,254)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.75","value":"-2.4"},{"groupId":"OG001","spread":"2.33","value":"-2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"title":"Week 22 (n=201,218)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"326"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"description":"Health outcome and quality of life as measured by NCCN/FACT FKSI-19 questionnaire. The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms specifically in renal cancer patients in 4 domains (Disease-Related Symptoms - Physical (FKSI-DRS-P), Disease-Related Symptoms - Emotional (FKSI-DRS-E), Treatment Side-Effects (FKSI-TSE), Function/Well-Being (FKSI-FWB)) experienced in the past 7 days. Participants are asked to respond to a total of 19 questions regarding symptoms, side effects, and well being by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 76). A negative mean indicates a worsening of condition.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Some participants were missing scores at Baseline and were excluded from the analysis. Participants missing scores at other early time points were excluded from the analysis at those time points. Change from Baseline was calculated as the assessment week value minus the Baseline value.","reportingStatus":"POSTED","timeFrame":"Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)","title":"Change From Baseline in the FACT-Kidney Symptom Index-19 (FKSI-19) Scale Treatment Side Effects (TSE) Domain Score at Day 28 of Cycles 1-4","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}